OH-CAS
15.12.2022 16:15:34 CET | Business Wire | Press release
CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid discovery for life sciences innovation.
CAS is expanding its comprehensive, highly structured, human-curated scientific data with the introduction of life sciences assets. The CAS Content CollectionTM now includes exhaustive biological sequences and bioactivity information designed to accelerate early-stage drug discovery research, with future additions including antibodies, omics, and more.
CAS is collaborating with Chemotargets to leverage Clarity® to serve as its technology foundation for rapid development, with future investments driving integration and expansion to cover the end-to-end pharmaceutical R&D workflow and accelerate therapeutic innovation.
“Unique insights derived from combining high-quality, comprehensive CAS scientific data with new technologies will enable drug discovery scientists to efficiently analyze how a modification in molecular structure may change the effect or toxicity of a drug, to evaluate drug-target-disease relationships, to assess freedom to operate in an area, and ultimately to design better, safer drugs with less financial risk,” said Manuel Guzman, President, CAS. “Our goal is to empower every aspect of drug discovery across scientific disciplines, including biology, and this expansion reflects a historic milestone on our path to accelerate life sciences research.”
CAS recently established a Life Sciences Industry Advisory Board comprising a world-class panel of global thought leaders from commercial, academic, and government organizations. These experts serve as trusted advisors, directing our scientific journey as we combine authoritative content with groundbreaking predictive technologies that span the spectrum of life sciences workflows. Under their advisement, CAS life sciences investments will continue, with focused content and capabilities to drive better decisions early in the drug discovery process… from understanding disease progression with its comprehensive biological pathway data to assessing the effectiveness of investigational drugs with enriched molecular biomarker data.
“Our enhanced capabilities, including predictive pharmacology tools and analytical visualization of drug-target-disease interactions, will be a leap forward for medicinal chemists and other drug discovery professionals,” according to Tim Wahlberg, Chief Product Officer, CAS. “Scientists will be able to leverage the most advanced relevance engine in the industry alongside new capabilities, not only to find inspiration for new ideas, but also to predict the viability and safety of drug candidates very early in the drug discovery process.”
About CAS
CAS is a leader in scientific information solutions, partnering with innovators around the world to accelerate scientific breakthroughs. CAS employs over 1,400 experts who curate, connect, and analyze scientific knowledge to reveal unseen connections. For over 100 years, scientists, patent professionals, and business leaders have relied on CAS solutions and expertise to provide the hindsight, insight, and foresight they need so they can build upon the learnings of the past to discover a better future. CAS is a division of the American Chemical Society. Connect with us at cas.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 11:00:00 CEST | Press release
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering. Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of
TOYO Corporation Opens Its Quantum Computers to Japan's Ecosystem15.9.2026 10:32:00 CEST | Press release
IQM Spark is TOYO's second quantum computer purchase, following its earlier acquisition of an IQM Radiance 20-qubit quantum computer. IQM will deliver both systems by the end of 2026. Both systems will be operational in early 2027 — the Spark system at TOYO's R&D center, and the Radiance 20 at AIST's Global Research and Development Center for Business by Quantum-AI technology (G-QuAT). TOYO will leverage the quantum infrastructure for its quantum initiatives, while extending access to Japan's wider quantum ecosystem. The move directly supports Japan's national quantum strategy, which targets 10 million domestic quantum users and ¥50 trillion in quantum-generated economic value by 2030. The deployments extend IQM's installed base across Asia-Pacific, following systems already delivered in South Korea and Taiwan. They also follow IQM's Nasdaq listing and an order backlog that has grown past €102 million. IQM Quantum Computers, a global leader in superconducting quantum computers, today a
Smartstream Further Enables Collateral Teams with Instant Answers and Controlled Automation through New MCP Servers15.9.2026 10:00:00 CEST | Press release
Key Facts Smart Collateral helps financial institutions manage the complete margin and collateral lifecycle, providing the control, visibility and governance required to operate at scale. Teams can now interact with that information in plain language, getting answers on agreements, eligibility, positions, margin calls and interest calculations without navigating multiple screens and reports across separate systems. Workflow actions, including creating or failing movements and issuing margin calls, are opt-in, so each firm decides exactly what an AI assistant is permitted to do. Two Model Context Protocol servers connect any MCP-compatible AI assistant to Smart Collateral: one for operating the platform’s APIs, one read-only over the reporting database. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces two new Model Context Protocol (MCP) servers for Smart Collateral, enabling dynamic, agentic collateral operation
More Than Half of Global Businesses Want Greater Control Over Their Data in Latest Digital Sovereignty Push, According to Expereo15.9.2026 10:00:00 CEST | Press release
The findings highlight the growing role of network visibility in digital sovereignty strategies as enterprises navigate increasingly complex cloud, AI and connectivity environments Businesses around the world are seeking greater control over their data as growing concerns around AI, security and compliance push digital sovereignty higher up the boardroom agenda, according to the latest IDC InfoBrief commissioned by Expereo*. More than half (53%) of enterprises say they want greater control over sensitive and strategic data, while 33% of global organizations now view digital sovereignty as a top or high priority. The research also found that 30% rank it among the leading drivers of technology investment, highlighting how governance, risk and compliance considerations are becoming increasingly important as organisations scale AI and cloud initiatives. The findings suggest organizations are looking beyond traditional approaches to data governance as they seek to better manage risk, regula
SES and Elveo Mobile Deepen Collaboration to Advance Direct-to-Device Services in Europe15.9.2026 09:30:00 CEST | Press release
SES, a global leader in space solutions, and Elveo Mobile, the company that delivers mobile connectivity and elevated intelligence for a planet on the move, today announced the expansion of their collaboration to accelerate delivery of direct-to-device (D2D) services in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915183604/en/ SES and Elveo Mobile Deepen Collaboration to Advance Direct-to-Device Services in Europe SES will leverage Elveo’s patented, proven and cost-effective D2D technology to enable seamless mobile roaming capabilities for European consumers, businesses, governments, institutional, and defense users. To further this vision, SES and Elveo Mobile will collaborate to establish manufacturing capabilities and a robust supply chain in Europe for the productions of the Low-Earth Orbit (LEO) D2D satellites, using Elveo’s patented D2D satellite bus, payload and software technology stack. These LEO D2D s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom